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To the Editor,
We wish to highlight the ongoing shortage of thiotepa in
the USA so that our colleagues may plan ahead accord-
ingly. We are not aware of similar shortages of this agent
affecting other countries.
In neuro-oncology, thiotepa is most often used for the
treatment of leptomeningeal metastases. It is recommended
for this indication in the most recently issued National
Comprehensive Cancer Network (NCCN) Guidelines.
In the Guidelines, it appears fourth in a list of nine, just
below (liposomal) cytarabine and methotrexate [1]. Along
with topotecan and etoposide, it is one of only three agents
which is indicated by general use (e.g. as opposed to
methotrexate where its use is specifically recommended for
lymphoma/leukemia and for breast cancer). Like most of
the agents on the list, its patent has expired.
Thiotepa has been approved by the US Food and Drug
Administration (FDA) for:
• bladder cancer (intravesical)
• ovarian and breast cancer (intravenous)
• malignant effusions (locally).
In all three conditions, it has been superseded by other
treatments and may be considered at best a ‘third-line’
agent. To our knowledge, approval has not been sought for
intrathecal use.
In the USA, the supply shortage came about in July
2014 following the acquisition of the product from the
former manufacturer, Bedford Laboratories, by Hikma
Pharmaceuticals. Currently, the only available FDA-ap-
proved distributor, Adienne SA, exports from Switzerland.
The manufacture occurs in Australia.
Pharmacies in the USA (including those which are
hospital-based) are unlikely to stock this medicine rou-
tinely and will need some advance notice if the drug is
required. Based on our experience, we expect a delay of
3–4 weeks between ordering and receiving thiotepa. We
became aware of the shortage while treating a patient with
ovarian cancer with leptomeningeal metastases. We
favored thiotepa as it is has been used for systemic treat-
ment of this condition.
Where use is expected in the upcoming year, it is
important to have reserves available. We suggest keeping
8–10 9 15 mg vials on hand. These can be reconstituted
locally to make the standard dose of 10 mg, which is given
twice/week. This should allow sufficient time for additional
supplies to arrive, if required. Storage of thiotepa is only
recommended for 1 year, so additional supplies may need
to be ordered on an annual basis.
Drug availability is a particular concern in this field,
where many of the agents commonly used no longer have
an active patent. Other examples are memantine and dex-
amethasone (IV), both of which are listed on the FDA’s
Drug Shortages Database as ‘‘Currently in Shortage’’ at the
time of writing [2]. To help the practitioner keep track of
such shortages, the FDA has recently developed a mobile
application [3].
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